SCHEMBL10106336

SCHEMBL10106336

COc1ccc(C2OCC(C)(C)CO2)cc1C(O)(c1cccc(Cl)c1)c1cc(C2OCC(C)(C)CO2)ccc1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NR3C1 P04150 1/20 0.35
MAPK1 P28482 1/20 0.34
CYP19A1 P11511 2/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
ALDH1A1 P00352 2/20 0.33
HTT P42858 1/20 0.33
MAPT P10636 3/20 0.33
GAA P10253 1/20 0.33
ALOX5 P09917 1/20 0.33
PTPN1 P18031 1/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
RBP4 P02753 1/20 0.32
CCR6 P51684 3/20 0.32
LMNA P02545 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10106322 0.88 RAB9A (0.39) SMN1; SMN2NPC1RAB9ANR3C1MAPK1
SCHEMBL10106346 0.87 NPC1 (0.39) SMN1; SMN2NPC1RAB9AMAPK1ALDH1A1
SCHEMBL10106383 0.86 SMN1; SMN2 (0.40) SMN1; SMN2NPC1RAB9ANR3C1MAPK1
SCHEMBL7074120 0.82 NPC1 (0.41) SMN1; SMN2NPC1RAB9ANR3C1MAPK1
SCHEMBL10106355 0.82 NPC1 (0.35) SMN1; SMN2NPC1RAB9AMAPK1MEN1
SCHEMBL10330556 0.78 NR3C1 (0.33) SMN1; SMN2NPC1RAB9ANR3C1
SCHEMBL10330568 0.77 NPC1 (0.33) SMN1; SMN2NPC1RAB9AMAPK1MEN1
SCHEMBL10106440 0.77 NPC1 (0.35) SMN1; SMN2NPC1RAB9A
SCHEMBL10106337 0.77 EGFR (0.41) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL10106449 0.75 NPC1 (0.34) SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-8119672-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-02-21 US disclosed
US-8119672-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-02-21 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES TTPA, HAVCR2, PML SMN1; SMN2 1044/4885NPC1 215/4885RAB9A 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.